• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Orphazyme A/S ADR (NQ: ORPH )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Mar 30, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Orphazyme A/S ADR

    < Previous 1 2 3 4 5 6 7 Next >
    TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    NASDAQ:ORPH Investor Notice: Deadline on September 7, 2021 in Lawsuit Against Orphazyme A/S
    San Diego, CA -- (SBWIRE) -- 08/26/2021 -- The Shareholders Foundation announced that a deadline is coming up on September 7, 2021 in the lawsuit filed for certain investors of Orphazyme A/S... 
    Via SBWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
    From CytRx Corporation
    Via Business Wire
    The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
    Via Benzinga
    The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
    Via Benzinga
    Earnings Scheduled For August 24, 2021
    Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is likely to report earnings for its second quarter. • Genetron Holdings (NASDAQ:GTH) is... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
    Via Benzinga
    Exposures COVID-19
    Dear ORPH Stock Fans, Here Is the Latest Trial News You Should Be Cheering
    Today, ORPH stock is trading significantly higher after the company announced some positive clinical trial data for its lead drug candidate. 
    Via InvestorPlace
    Investors React Positively To Data From Orphazyme's Neurodegenerative Disease Candidate
    Orphazyme A/S (NASDAQ: ORPH) announced that results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) had been published in the peer-... 
    Via Benzinga
    66 Biggest Movers From Yesterday
    Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    What's Next For Orphazyme Stock?
    Orphazyme A S ADR (NASDAQ: ORPH) shares are higher Wednesday, as traders were able to push the stock up. There looks to be no company-specific news to cause the jump in share... 
    Via Benzinga
    85 Biggest Movers From Yesterday
    Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
    Via Benzinga
    Dear ORPH Stock Fans, Mark Your Calendars for August 31
    Today, investors appear to be pricing some positive news and a potential short squeeze into ORPH stock, as Orphazyme shoots higher. 
    Via InvestorPlace
    Stocks That Hit 52-Week Lows On Thursday
    During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low... 
    Via Benzinga
    The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
    Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company with the largest market cap to set a new 52-week low was... 
    Via Benzinga
    ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investors With Losses Exceeding $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
    From The Rosen Law Firm, P.A.
    Via Business Wire
    The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
    Via Benzinga
    NASDAQ: ORPH Investor Notice: Lawsuit Alleges Securities Laws Violations by Orphazyme A/S
    San Diego, CA -- (SBWIRE) -- 07/28/2021 -- A lawsuit was filed on behalf of investors in Orphazyme A/S (NASDAQ: ORPH) shares over alleged securities laws violations. 
    Via SBWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
    From Law Offices of Howard G. Smith
    Via Business Wire
    Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investors With Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
    From The Rosen Law Firm, P.A.
    Via Business Wire
    The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    SHAREHOLDER ALERT: Robbins LLP Announces that Orphazyme A/S (ORPH) is Being Sued for Misleading Shareholders
    From Robbins LLP
    Via Business Wire
    Orphazyme Stock Is a Dead-End for Investors After FDA Rejection
    ORPH stock has a virtually impossible task ahead of it in picking itself after FDA's rejection of the Danish biopharma's Arimoclomol drug. 
    Via InvestorPlace
    Exposures Product Safety
    The Law Offices of Frank R. Cruz Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.